J Med Microbiol NEW Faster Access
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Senaratne, R. H.
Right arrow Articles by Riley, L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Senaratne, R. H.
Right arrow Articles by Riley, L. W.
Agricola
Right arrow Articles by Senaratne, R. H.
Right arrow Articles by Riley, L. W.
J Med Microbiol 56 (2007), 454-458; DOI: 10.1099/jmm.0.46983-0
© 2007 Society for General Microbiology
ISSN 1473-5644

Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant

Ryan H. Senaratne1, Joseph D. Mougous2, J. Rachel Reader3, Spencer J. Williams2,{dagger}, Tianjiao Zhang1, Carolyn R. Bertozzi2,4,5 and Lee W. Riley1

1 School of Public Health, University of California, Berkeley, CA 94720, USA

2 Department of Chemistry, University of California, Berkeley, CA 94720, USA

3 Comparative Pathology Laboratory, School of Veterinary Medicine, University of California, Davis, CA 95616, USA

4 Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA

5 Howard Hughes Medical Institute, University of California, Berkeley, CA 94720, USA

Correspondence
Carolyn R. Bertozzi
crb{at}berkeley.edu
Lee W. Riley
lwriley{at}berkeley.edu

Received 4 October 2006
Accepted 21 November 2006

The emergence of drug-resistant Mycobacterium tuberculosis strains and the widespread occurrence of AIDS demand newer and more efficient control of tuberculosis. The protective efficacy of the current Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccine is highly variable. Therefore, development of an effective new vaccine has gained momentum in recent years. Recently, several M. tuberculosis mutants were tested as potential vaccine candidates in the mouse model of tuberculosis. However, only some of these mutants were able to generate protection equivalent to that of BCG in mice. This study reports the vaccine potential of an attenuated 5'-adenosine phosphosulfate reductase mutant ({Delta}cysH) of M. tuberculosis. Immunization of mice with either BCG or {Delta}cysH followed by infection with the virulent M. tuberculosis Erdman strain demonstrated that {Delta}cysH can generate protection equivalent to that of the BCG vaccine.

Abbreviations: BCG, bacille Calmette–Guérin; H&E, haematoxylin and eosin; p.i., post-infection; TB, tuberculosis.

{dagger}Present address: School of Chemistry and Bio21 Molecular Science and Biotechnology Institute, Victoria 3010, Australia.




This article has been cited by other articles:


Home page
 Infect. Immun.Home page
M. V. Tullius, G. Harth, S. Maslesa-Galic, B. J. Dillon, and M. A. Horwitz
A Replication-Limited Recombinant Mycobacterium bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious than BCG
Infect. Immun., November 1, 2008; 76(11): 5200 - 5214.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 2007 Society for General Microbiology.